Kirkland Guides Bristol-Myers' $520M Cancer Drug Co. Buy
Bristol-Myers Squibb Co. will pay as much as $520 million to boost its cancer therapy pipeline with the acquisition of Swedish drug developer Cormorant Pharmaceuticals in a deal guided by Kirkland...To view the full article, register now.
Already a subscriber? Click here to view full article